Please Wait...

Jeffrey Heilbraun

Translation skills

Main profile

Jeffrey S. Heilbraun
Director, Strategic Development

Jeffrey Heilbraun attended Tufts University in Boston, Massachusetts where he completed his Bachelor of Science degree in Biology with a focus on physiology. Jeff continued his studies at The American University in Washington D.C., receiving a fellowship and completing his Masters of Science in Health Promotion and Disease Management. He was employed at The American University as an adjunct professor in the Health Promotion program. Throughout his career, Jeff has maintained his focus on the science and physiology behind cardiac safety within pharmaceutical development, with a special interest in hemodynamics. Jeff has presented posters and session participation at the Drug Information Association (DIA) meeting, American Society of Hypertension (ASH), Canadian Clinical Pharmacology Association and recently at the Cardiac Safety Research Consortium (CSRC).

Featured White Paper from the Cardiac Safety Research Consortium

Authored Publications

Sager P, Heilbraun J, Turner JR, Gintant G, Geiger MJ, Kowey PR, Mansoor GA, Mendzelevski B, Michelson EL, Stockbridge N, Weber MA, White WB. Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J. 2013 Apr;165(4):477-88. doi: 10.1016/j.ahj.2013.01.002.

Braddock M, Heilbraun J, Mendzelevski B. Cardiovascular safety and hemodynamic considerations in oncology drug development -- webinar highlights October 10th 2012Expert Opin Drug Saf. 2013 Sep;12(5):783-91. doi: 10.1517/14740338.2013.797407. Epub 2013 May 8. PMID: 23651420

Blogs

If you are in clinical development and interested in latest developments in cardiac safety blood pressure (BP) requirements, I encourage you to attend a public workshop announced by the U.S. Food and Drug Administration (FDA) entitled "Evaluating the Pressor Effects of Drugs & Ambulatory Blood Pressure Monitoring Studies." This workshop is convened by the Duke-Robert J.

Blood pressure monitor

— Part 2 in a 3-part blog series on cardiac safety regulatory developments

Thanks to scientific advancements and increased understanding of pathways and systems that contribute to cardiac risk, the cardiac safety ECG environment continues to mature and expand. Presently, the assessment of QT/QTc from the electrocardiogram is the primary focal endpoint in cardiac safety.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica SMART Our Digital Customer Portal Allows Sites and Sponsors to Benefit from Real-Time Access to Their Tr… https://t.co/VJi2kVttFu
Bioclinica (13 hours ago)
Bioclinica will be gold sponsors at the upcoming World Drug Safety Congress in Europe. Meeting with our team to le… https://t.co/7efqU3ZHb8
Bioclinica (2 days ago)
Bioclinica Cardiac Safety Services Offered a Unique Solution for a Specific Regulatory Requirement. Read our case s… https://t.co/4j1AUk6YDz
Bioclinica (5 days ago)
Agile IRT is here! How can you benefit? Download our webinar to know more. #bioclinica #irt #clinicaltrials… https://t.co/zH5aFYxxUf
Bioclinica (6 days ago)
Bioclinica's Electronic Data Capture #EDC has been used in thousands of clinical studies worldwide. Why? Our single… https://t.co/g427VOUSFS
Bioclinica (1 week ago)
Bioclinica will be exhibiting at the upcoming #SCDM2019 – the industry’s largest clinical data management event of… https://t.co/JLTSWOI8rl
Bioclinica (2 weeks ago)